The FDA has approved three GLP-1s in particular for both type 2 diabetes treatment and weight loss: Liraglutide (Saxenda, Victoza): While effective, this once-daily injection generally leads to more modest weight loss compared to newer options (its been around since 2014)
2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
BMI was of the highest values in liraglutide group and of lowest values in the control group (p = 0.024)
In this context, the purpose of the present article is to review the status of the gliptins currently in clinical use, with special emphasis on their capabilities to positively or negatively affect the cardiovascular system, and their potential involvement in major adverse cardiovascular events (MACE)
These medications are administered via subcutaneous injection, typically weekly (semaglutide) or daily (liraglutide)